Previous 10 | Next 10 |
Shares of Reata Pharmaceuticals (NASDAQ: RETA) are up 59% at 12:26 p.m. EDT, after the company released positive data for the midstage Moxie study of its drug candidate, omaveloxolone, in patients with a neuromuscular disease called Friedreich's ataxia. As biotech investors have seen time...
Gainers: Westwater Resources (NASDAQ: WWR ) +108% . TDH Holdings (NASDAQ: PETZ ) +74% . Reata Pharmaceuticals (NASDAQ: RETA ) +60% . Ra Medical Systems (NYSE: RMED ) +25% . Aphria (NYSE: APHA ) +25% . Abeona Therapeutics (NASDAQ: ABEO ) +25% . CannTrust Holdings (NYSE: CTST ) ...
Westwater Resources (NASDAQ: WWR ) +130% on receiving first shipment of graphite concentrate. More news on: Westwater Resources, Inc., Reata Pharmaceuticals, Inc., NF Energy Saving Corporation, Stocks on the move, Read more ...
Reata Pharmaceuticals (NASDAQ: RETA ) announces positive results from the registrational portion of its Phase 2 clinical trial, MOXIe , evaluating omaveloxolone in patients with a rare inherited neurodegenerative disorder called Friedreich's ataxia (FA). More news on: Reata Pharmaceut...
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR OCTOBER 15, 2019, AT 8:00 AM ET IRVING, Texas, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc....
IRVING, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl (bardoxolone) will be presented at the American Soc...
Reata Pharmaceuticals (NASDAQ: RETA ) has reacquired development and commercialization rights to its Nrf2 activator product platform from licensee AbbVie (NYSE: ABBV ). Specifically, it owns exclusive global rights bardoxolone methyl, omaveloxolone and all other next-generation Nrf2 activa...
IRVING, Texas, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform or...
Insider buying more than doubled last week with insiders purchasing $125.79 million of stock last week compared to $57.61 million in the week prior. Selling, on the other hand, declined with insiders selling $508.49 million of stock last week compared to $683.67 million in the week prior. S...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Outperform rating and $146 (45% upside) price target at William Blair. More news on: Alexion Pharmaceuticals, Inc., Change Healthcare Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...